Innate Pharma SA
OTC:IPHYF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Innate Pharma SA
OTC:IPHYF
|
FR |
|
I
|
Integra Lifesciences Holdings Corp
F:IL3
|
US |
|
C
|
Cronos Group Inc
F:7CI
|
CA |
|
El Puerto de Liverpool SAB de CV
F:PLV1
|
MX |
Wall St Price Targets
IPHYF Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for
IPHYF is 5.79 USD with a low forecast of 4.83 USD and a high forecast of 6.91 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IPHYF's stock price target?
Price Target
5.79
USD
According to Wall Street analysts, the average 1-year price target for
IPHYF is 5.79 USD with a low forecast of 4.83 USD and a high forecast of 6.91 USD.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.